Movano (MOVE) Opens Investigation to Expose Apparent Stock Manipulation

Movano Health (Nasdaq: MOVE) (the "Company") announced today that it has opened an investigation to expose apparent manipulation in trading of the Company's common shares, following the recent announcement of a shareholder approved reverse stock split.

"We are committed to transparency and protecting the interests of our Company and shareholders," said John Mastrototaro, President and CEO of Movano Health. "It has come to our attention that several small cap stocks have suffered similar manipulation in recent weeks following their respective reverse stock splits, and we are in direct communication with securities regulators, legal counsel and other interested partners, as we pursue this issue to the fullest extent necessary."

Additional information regarding the Reverse Stock Split can be found in the Company's definitive proxy statement for the annual meeting of stockholders of the Company held on July 9, 2024, which was filed with the U.S. Securities and Exchange Commission on May 28, 2024, a copy of which is available at www.sec.gov and on the Company's website.

You May Also Be Interested In

• Sonoma Pharmaceuticals posts 60% revenue rise, first positive EBITDA
• Creative Medical gets patent allowance for exosome-based T1D therapy
• Definitive Healthcare launches early adopter program for AI platform